Amicus Therapeutics

$10.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.31 (-2.91%) Today
-$0.29 (-2.80%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell FOLD and other stocks, options, and ETFs commission-free!

About FOLD

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with rare metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Cranbury, NJ. The listed name for FOLD is Amicus Therapeutics, Inc. Common Stock.

CEO
John Francis Crowley
Employees
584
Headquarters
Philadelphia, Pennsylvania
Founded
2002
Market Cap
2.97B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
5.96M
High Today
$10.90
Low Today
$10.05
Open Price
$10.60
Volume
4.90M
52 Week High
$25.39
52 Week Low
$6.25

FOLD News

BenzingaMar 1

Amicus Therapeutics: Q4 Earnings Insights

Shares of Amicus Therapeutics (NASDAQ:FOLD) moved higher by 0.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per s
BenzingaFeb 26

Earnings Preview for Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) unveils its next round of earnings this Monday, March 01. Get prepared with Benzinga's ultimate preview for Amicus Therapeutic

FOLD Earnings

-$0.36
-$0.31
-$0.25
-$0.20
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.23 per share
Actual
-$0.27 per share
Replay Earnings Call

You May Also Like

PBSM
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure